|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GlaxoSmithKline |
| Information provided by: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00344513 |
Purpose
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.
| Condition | Intervention | Phase |
|
Heart Failure |
Drug: Beta-blockers including Carvedilol Drug: ACE inhibitors |
Phase IV |
| Genetics Home Reference related topics: | Heart Diseases |
| MedlinePlus related topics: | Heart Failure |
| ChemIDplus related topics: | Carvedilol |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-Based Registry and Process of Care Improvement Program for Heart Failure Patients |
| Estimated Enrollment: | 50000 |
| Study Start Date: | December 2002 |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations
More Information
| Study ID Numbers: | 105517/358 |
| First Received: | June 23, 2006 |
| Last Updated: | June 23, 2006 |
| ClinicalTrials.gov Identifier: | NCT00344513 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|